Cargando…

Serum levels of AgRP protein in patients with schizophrenia on clozapine monotherapy

Aim: Agouti-related peptide (AgRP) is one of the hypothalamic hormones that works by increasing appetite and decreasing metabolism, thus leading to weight gain. The aim of the study was to find out if AgRP level in subjects with schizophrenia on clozapine monotherapy is higher compared with healthy...

Descripción completa

Detalles Bibliográficos
Autores principales: Wysokiński, Adam, Kaźmierski, Jakub, Kłoszewska, Iwona
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4351436/
https://www.ncbi.nlm.nih.gov/pubmed/25034457
http://dx.doi.org/10.1007/s11011-014-9592-6
_version_ 1782360321539702784
author Wysokiński, Adam
Kaźmierski, Jakub
Kłoszewska, Iwona
author_facet Wysokiński, Adam
Kaźmierski, Jakub
Kłoszewska, Iwona
author_sort Wysokiński, Adam
collection PubMed
description Aim: Agouti-related peptide (AgRP) is one of the hypothalamic hormones that works by increasing appetite and decreasing metabolism, thus leading to weight gain. The aim of the study was to find out if AgRP level in subjects with schizophrenia on clozapine monotherapy is higher compared with healthy controls. Methodology: We determined fasting serum AgRP levels in 24 subjects with schizophrenia on clozapine monotherapy and 24 healthy, age- and sex-matched controls. Biochemical and anthropometric measurements were combined with body composition analysis. Results: There was no difference for AgRP levels between patients taking clozapine and control group (15.00±8.65 vs. 15.33±6.82 pg/mL, p =0.37). We found negative correlations between AgRP levels and total body fat (r =−0.34 and −0.48 in the whole study group and clozapine group, respectively) and positive correlations with lean body mass (r =0.38 and 0.49 in the whole study group and clozapine group, respectively), body water (r =0.34 and 0.49 in the whole study group and clozapine group, respectively) and basal metabolic rate (r =0.42 both in the clozapine and control groups). There were no correlations with age, height, weight, body mass index, fat mass index, abdominal, waist or hip circumferences, waist-hip ratio, blood pressure, total cholesterol, HDL, LDL, triglycerides, uric acid, glucose, insulin, clozapine dose or treatment duration, duration of treatment with antipsychotics and markers for insulin resistance. Conclusion: We cannot conclude that treatment with clozapine is associated with increased level of AgRP. We did not find previously described differences in AgRP levels between obese and non-obese subjects or associations between AgRP and various metabolic parameters.
format Online
Article
Text
id pubmed-4351436
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-43514362015-03-11 Serum levels of AgRP protein in patients with schizophrenia on clozapine monotherapy Wysokiński, Adam Kaźmierski, Jakub Kłoszewska, Iwona Metab Brain Dis Research Article Aim: Agouti-related peptide (AgRP) is one of the hypothalamic hormones that works by increasing appetite and decreasing metabolism, thus leading to weight gain. The aim of the study was to find out if AgRP level in subjects with schizophrenia on clozapine monotherapy is higher compared with healthy controls. Methodology: We determined fasting serum AgRP levels in 24 subjects with schizophrenia on clozapine monotherapy and 24 healthy, age- and sex-matched controls. Biochemical and anthropometric measurements were combined with body composition analysis. Results: There was no difference for AgRP levels between patients taking clozapine and control group (15.00±8.65 vs. 15.33±6.82 pg/mL, p =0.37). We found negative correlations between AgRP levels and total body fat (r =−0.34 and −0.48 in the whole study group and clozapine group, respectively) and positive correlations with lean body mass (r =0.38 and 0.49 in the whole study group and clozapine group, respectively), body water (r =0.34 and 0.49 in the whole study group and clozapine group, respectively) and basal metabolic rate (r =0.42 both in the clozapine and control groups). There were no correlations with age, height, weight, body mass index, fat mass index, abdominal, waist or hip circumferences, waist-hip ratio, blood pressure, total cholesterol, HDL, LDL, triglycerides, uric acid, glucose, insulin, clozapine dose or treatment duration, duration of treatment with antipsychotics and markers for insulin resistance. Conclusion: We cannot conclude that treatment with clozapine is associated with increased level of AgRP. We did not find previously described differences in AgRP levels between obese and non-obese subjects or associations between AgRP and various metabolic parameters. Springer US 2014-07-19 2015 /pmc/articles/PMC4351436/ /pubmed/25034457 http://dx.doi.org/10.1007/s11011-014-9592-6 Text en © The Author(s) 2014 https://creativecommons.org/licenses/by/4.0/ Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
spellingShingle Research Article
Wysokiński, Adam
Kaźmierski, Jakub
Kłoszewska, Iwona
Serum levels of AgRP protein in patients with schizophrenia on clozapine monotherapy
title Serum levels of AgRP protein in patients with schizophrenia on clozapine monotherapy
title_full Serum levels of AgRP protein in patients with schizophrenia on clozapine monotherapy
title_fullStr Serum levels of AgRP protein in patients with schizophrenia on clozapine monotherapy
title_full_unstemmed Serum levels of AgRP protein in patients with schizophrenia on clozapine monotherapy
title_short Serum levels of AgRP protein in patients with schizophrenia on clozapine monotherapy
title_sort serum levels of agrp protein in patients with schizophrenia on clozapine monotherapy
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4351436/
https://www.ncbi.nlm.nih.gov/pubmed/25034457
http://dx.doi.org/10.1007/s11011-014-9592-6
work_keys_str_mv AT wysokinskiadam serumlevelsofagrpproteininpatientswithschizophreniaonclozapinemonotherapy
AT kazmierskijakub serumlevelsofagrpproteininpatientswithschizophreniaonclozapinemonotherapy
AT kłoszewskaiwona serumlevelsofagrpproteininpatientswithschizophreniaonclozapinemonotherapy